Quantitative determination of intracellular Asulacrine in MCF-7 breast cancer cells by liquid chromatography-mass spectrometry and its application to cellular pharmacokinetic studies of P188 modified liposomes

• Published in: Biomedical chromatography Vol. 30; no. 12; pp. 1908 - 1914
• Main Authors: Zang, Xiaojie, Zhang, Jingwei, Zhou, Yaqian, Chen, Qianying, Peng, Ying, Sun, Jianguo, Liu, Jiali, Liu, Wenyue, Wang, Guangji, Zhou, Fang
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2016
• Subjects: Amsacrine - analogs & derivatives; Amsacrine - pharmacokinetics; Antineoplastic Agents - pharmacokinetics; asulacrine; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Chromatography, Liquid - methods; Female; Humans; intracellular concentration; LC/MS; liposome; Liposomes; Mass Spectrometry - methods; MCF-7 Cells; Reproducibility of Results; LC/MS; asulacrine; intracellular concentration; liposome
• ISSN: 0269-3879; 1099-0801
• DOI: 10.1002/bmc.3762

Asulacrine (ASL), an analogue of amsacrine, has shown higher anti‐breast and anti‐lung cancer activity. Hereby, a new sensitive and selective liquid chromatography–mass spectrometry (LC/MS) method was developed to determine intracellular asulacrine. The chromatographic separation was performed on an Agilent Zorbax Extend‐C18 column (2.1 mm i.d. × 50 mm, 5 μm) using gradient elution with water (2 mmol/L ammonium acetate and 0.1% acetic acid) and acetonitrile as the mobile phase. The detection was achieved with selected ion monitoring mode using electrospray ionization in positive mode with target ions at m/z 465.3 and m/z 326.1 for asulacrine and midazolam, respectively. The standard curve showed a good linearity with the lower limit of quantification of 1 ng/mL, as a result of which, the trace concentration of ASL in cell suspension could be quantified. The intra‐ and inter‐day accuracy ranged from −5.28 to 6.5% and from −6.32 to 1.05%, and the intra‐ and inter‐day precisions were no more than 7.65% and 11.71%, respectively. Additionally, no degradation of asulacrine was observed during stability evaluation. The method was proved to be powerful and practical to determine and compare the intracellular distribution and kinetics of ASL under different formulations in MCF‐7 breast cancer cells.